FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NextGen Nordics Strengthens Insights on Innovation Divide and AI Integration

Upcoming data reveals crucial trends in the Nordic fintech landscape.Highlights: NextGen Nordics to reveal data on fintech innovation...
FinTech

US Launches Cybersecurity Sharing Channel for Crypto Firms

New initiative aims to enhance security in the cryptocurrency sector.Highlights: US government launches a new cybersecurity sharing channel...
FinTech

PayPal Expands Payment Links to Canva Creators

Canva users can now easily monetize their designs with PayPal's new feature.Highlights: PayPal's payment links feature is now...
FinTech

Perpetuals Strengthens AI with Quantum Resilience as a Service

The new offering promises enhanced stability and security for fintech operations.Highlights: Perpetuals launches unique Quantum Resilience as a...